Silencer® siRNA Transfection II Kit

Catalog Number AM1631
Publication Number 1631M
Revision D
Contents

■ Silencer® siRNA Transfection II Kit ............................................. 5
  Introduction .................................................................................. 5
  Background .................................................................................. 5
  Product description ....................................................................... 5
  Silencer® siRNA Transfection II Kit components and storage .......... 6
  Required materials not provided .................................................. 7
  Optimizing transfection ............................................................... 7
    Parameters that impact transfection efficiency ......................... 7
    Optimization overview ............................................................... 8
    Initial transfection protocol to select transfection agent .............. 10
    Optimizing siRNA transfection conditions ................................. 11
  Troubleshooting ........................................................................... 13
    No detectable gene silencing ..................................................... 13
    Transfection causes extensive cell death .................................. 14
    Gene silencing experiments lack reproducibility ....................... 14

■ APPENDIX A Supplemental Information ................................. 15
  Related products available from Life Technologies ...................... 15

■ APPENDIX B Assessing Transfection Efficiency ..................... 17
  Using the KDalert™ Kit to monitor cytotoxicity and GAPDH knockdown ................................................................. 17
  Other cell viability assays ........................................................... 18
  Other assays for gene knockdown ............................................... 18

■ APPENDIX C Traditional “Pre-plating” Transfection Protocol ..... 21
  Traditional transfection protocol .................................................. 21
  Protocol modification for cotransfection ...................................... 22

■ APPENDIX D Safety ................................................................. 23
  Chemical safety ............................................................................ 23
  Biological hazard safety ............................................................... 23
Documentation and Support .......................................................... 25

Obtaining SDSs ............................................................................. 25
Obtaining support .......................................................................... 25
Limited product warranty ............................................................... 25

Bibliography .................................................................................. 27
Silencer® siRNA Transfection II Kit

IMPORTANT! Before using this product, read and understand the information in the “Safety” appendix in this document.

Introduction

Background

RNA interference (RNAi), or gene silencing, is a technique for down-regulating the expression of a specific gene in living cells by introducing a double-stranded RNA (dsRNA) that is complementary to a target mRNA of interest. It has been demonstrated that 21 basepair (bp) RNA molecules (small interfering RNA or siRNA) can be a potent mediator of the RNAi effect in mammalian cells (Elbashir et al. 2001).

The choice of a transfection agent for delivery of siRNA is critical for gene silencing experiments. Without efficient transfection, siRNA will fail to elicit a cellular response. Most commercially available transfection agents were developed for plasmid transfections and many are limited in their efficacy to only a few cell types. The Silencer® siRNA Transfection II Kit contains two different transfection agents and controls for optimizing siRNA transfection.

Product description

Transfection agents

Because different cell types respond differently to transfection conditions, the Ambion® Silencer® siRNA Transfection II Kit includes two transfection agents, siPORT™ NeoFX™ and siPORT Amine. Each transfection agent has different properties to support siRNA transfection of a broad range of cell types with high efficiency and reproducibility. siPORT NeoFX is a proprietary mixture of lipids and siPORT Amine is a proprietary blend of polyamines. These reagents function by complexing with siRNAs and facilitating their transfer into cells. Both reagents are easy to use and have minimal cytotoxic effects.

Controls

This kit includes positive and negative siRNA controls for use in optimization experiments. The positive siRNA control, targeting the glyceraldehyde-3-phosphate dehydrogenase (GAPDH) gene, has been verified to induce silencing in human, mouse, and rat cell lines. The Negative Control siRNA is a scrambled sequence that bears no homology to the human, mouse, or rat genomes.
Reverse transfection

This Instruction Manual provides instructions for optimization by a newly developed transfection method—reverse transfection, or neofection. It is a transfection method in which cells are transfected as they adhere to a plate after trypsinization (Figure 1). This method bypasses several steps of the traditional “pre-plating” transfection method, making it faster and easier. We recommend neofection for convenience and ease. Furthermore, it can be used with both siPORT NeoFX and siPORT Amine, and it is effective in most cell types. Protocols for traditional transfection are provided in the Appendix (Appendix C, “Traditional “Pre-plating” Transfection Protocol” on page 21).

Kit applications

The Silencer® siRNA Transfection II Kit is designed for transfection of small RNAs, including siRNAs and miRNAs. This kit can also be used for co-transfection of DNA molecules, such as plasmids or PCR products (see “Protocol modification for cotransfection” on page 22 for details).

This kit is primarily intended for transfection of adherent cells.

**Figure 1** Overview of siRNA Transfection Protocol.

<table>
<thead>
<tr>
<th>Amount</th>
<th>Component</th>
<th>Storage</th>
</tr>
</thead>
<tbody>
<tr>
<td>400 µL</td>
<td>siPORT™ NeoFX™ Transfection Agent</td>
<td>4°C</td>
</tr>
<tr>
<td>400 µL</td>
<td>siPORT Amine Transfection Agent</td>
<td>4°C†</td>
</tr>
<tr>
<td>50 µL</td>
<td>GAPDH siRNA, 20 µM</td>
<td>−20°C</td>
</tr>
<tr>
<td>30 µL</td>
<td>Negative Control siRNA, 20 µM</td>
<td>−20°C</td>
</tr>
</tbody>
</table>

† Do not freeze.

**IMPORTANT!** Keep the tubes of siPORT NeoFX and siPORT Amine tightly closed to prevent evaporation.
**Required materials**

<table>
<thead>
<tr>
<th>not provided</th>
</tr>
</thead>
</table>

**Cell culture material and equipment**
- OPTI-MEM® I Reduced-Serum Medium (Cat no. #31985-070)
- Routine tissue culture supplies and equipment

**Detection of GAPDH silencing**
Materials for measuring gene knockdown—knockdown can be assessed by measurement of GAPDH enzyme activity, Northern blot analysis, real-time RT-PCR, or indirectly by cell proliferation assays.

The KDalert™ GAPDH Assay Kit (Cat. no. AM1639) provides a quick assay for both GAPDH gene knockdown and cell viability.

**For silencing the target of interest**
- siRNA to the gene of interest
- Reagents and equipment to detect gene silencing

---

**Optimizing transfection**

**Parameters that impact transfection efficiency**

**Transfection agent**
- siPORT Amine or siPORT NeoFX
  It is important to select the appropriate siPORT transfection agent for the cell line under study. Different cell types vary in their response to different transfection agents; thus, the best transfection agent for a particular cell type must be determined experimentally.
  - Volume of transfection agent
  The volume of transfection agent used is a critical parameter to optimize; too little can limit transfection, but too much can be toxic. The overall transfection efficiency is influenced by the amount of transfection agent complexed to the siRNA. This critical volume should be determined empirically for each cell line. A recommended range and starting volume are provided in the protocol.
  - Exposure to transfection agent
  Although the siPORT transfection agents were designed to minimize cytotoxicity, exposing cells to excessive amounts of transfection agent or for extended time periods can be detrimental to the overall health of the cell culture.

**siRNA**
- siRNA quality
  The quality of siRNA can significantly influence RNAi experiments. siRNA should be free of reagents carried over from synthesis, such as salts and proteins. Also, dsRNA contaminants longer than 30 bp are known to cause cytotoxicity. We recommend using column, HPLC, or gel purified, chemically synthesized siRNAs to ensure quality and purity. Life Technologies offers an extensive line of options for chemically synthesized siRNAs; visit www.lifetechnologies.com/sirna.
• siRNA quantity
   The optimal amount of siRNA and its capacity for gene silencing are influenced in part by properties of the target gene, including the following: mRNA localization, stability, and abundance, and target protein stability and abundance. If too much siRNA is used for transfection, it may lead to off-target effects. Conversely, if too little siRNA is transfected, reduction of target-gene expression may be undetectable. Because there are so many variables involved, it is important to optimize the siRNA amount for every cell line used, and in some cases, it may even be necessary to re-optimize for different targets.

Cell culture
• Use healthy cells
   In general, healthy cells transflect better than poorly maintained cells. Routinely subculturing cells before they become overcrowded or unhealthy will minimize instability in continuous cell lines from experiment to experiment. Information on basic cell culture technique can be found in Culture of Animal Cells: A Manual of Basic Technique (Freshney, 2000).
• Transfect cells within 10 passages of optimization experiments
   Since cells may gradually change in culture, we recommend transfecting cells within 10 passages of determining optimal transfection conditions. If transfection efficiency begins to drop, fresh cells should be thawed for subsequent experiments.
• Presence of serum in the medium during transfection
   Both siPORT Amine and siPORT NeoFX are compatible with transfection in serum-containing normal growth medium. No culture medium replacement or addition is required after transfection.

Optimization overview
The point of optimization is to determine the conditions that will provide good gene knockdown while maintaining an acceptable level of cell viability for the particular cell type. Some of the conditions that improve gene knockdown (e.g., amount of transfection agent) also result in decreased cell viability. Therefore, both gene knockdown and cell viability should be considered when interpreting optimization experiments—with a balance between the two representing the ideal conditions for transfection. Once optimal conditions are established, they should be kept constant between experiments for a given cell type.
**Figure 2** *Silencer® siRNA Transfection II Kit Optimization*. First, follow the protocol in section “Initial transfection protocol to select transfection agent” on page 10 to evaluate the effectiveness of siPORT Amine and siPORT NeoFX. If one of the transfection agents yields acceptable results, no further optimization is needed. Otherwise, continue the optimizations outlined in section “Optimizing siRNA transfection conditions” on page 11 using the transfection agent that performed the best in your initial screen. Once an acceptable level of knockdown and cell viability is obtained, no further optimization is needed.

Conduct optimization experiments with the control siRNAs

In each experiment, run controls in replicate using the GAPDH siRNA and the Negative Control siRNA.

When successfully transfected, the **GAPDH siRNA** reduces both the mRNA and protein levels of GAPDH in human, mouse, and rat cell lines. This slows the growth rate of the cells and reduces the rate of cell proliferation of most cell types.

The **Negative Control siRNA** is a scrambled sequence that has no significant homology to the human, mouse, or rat genome. The Negative Control siRNA should have no effect on the mRNA and protein levels of GAPDH; it serves as a baseline for measuring the effects of the GAPDH siRNA. The negative control can be used to identify nonspecific effects such as nonspecific-siRNA effects, cytotoxicity of the transfection agent and/or the siRNA, or suboptimal transfection conditions.

Include a buffer-only control

To control for any nontransfection related phenomena, always include a sample well that is mock-transfected with OPTI-MEM medium and siRNA buffer, but lacks transfection agent and siRNA.
Initial transfection protocol to select transfection agent

For the most rapid assay development, we provide suggested initial conditions. Use these conditions in your first experiments and optimize as needed based on the results.

1. Prepare cells
   a. Trypsinize adherent cells.
      Trypsinize healthy, growing, adherent cells using your routine procedure.
   b. Resuspend cells to 1 x 10^5 cells/mL in normal growth medium.
      Inactivate trypsin by resuspending the cells in normal growth medium to reach a concentration of 1 x 10^5 cells/mL. Keep the cells at 37°C while preparing the transfection complexes (below).
      **Note:** Cells should be transfected before they re-adhere; proceed immediately with the following steps.

2. Prepare RNA/transfection agent complexes and distribute into culture plate wells
   The instructions below give examples of reagent amounts to use per well for 96-, 24-, 12-, or 6-well plates.
   - When possible, prepare master mixes to minimize variability.
   - Bring the transfection agent and the OPTI-MEM I medium to room temperature before use. Briefly centrifuge the transfection agent before use to pool liquid at the bottom of the tube.
   - For preparation of RNA and reagent dilutions, use a sterile polystyrene culture plate (round or V-bottom) or 12 x 75 mm tubes.
   a. Dilute the transfection agent in OPTI-MEM I medium.

<table>
<thead>
<tr>
<th>Reagent</th>
<th>96-well</th>
<th>24-well</th>
<th>12-well</th>
<th>6-well</th>
</tr>
</thead>
<tbody>
<tr>
<td>siPORT NeoFX (µL)</td>
<td>0.5</td>
<td>1.5</td>
<td>3</td>
<td>5</td>
</tr>
<tr>
<td>OPTI-MEM I to (µL)</td>
<td>10</td>
<td>25</td>
<td>50</td>
<td>100</td>
</tr>
</tbody>
</table>

b. Incubate 10 min at room temp.

c. Dilute the RNA in OPTI-MEM I medium for a final concentration of 30 nM in the transfection

<table>
<thead>
<tr>
<th>Reagent</th>
<th>96-well</th>
<th>24-well</th>
<th>12-well</th>
<th>6-well</th>
</tr>
</thead>
<tbody>
<tr>
<td>20 µM small RNA</td>
<td>0.15 µL</td>
<td>0.75 µL</td>
<td>1.5 µL</td>
<td>3.75 µL</td>
</tr>
<tr>
<td>OPTI-MEM I to:</td>
<td>10 µL</td>
<td>25 µL</td>
<td>50 µL</td>
<td>100 µL</td>
</tr>
</tbody>
</table>

d. Mix diluted RNA and diluted transfection agent. Incubate at room temp for 10 min.
   Combine the diluted transfection agent from step a. with the diluted RNA from step c. Mix by pipetting up and down or flicking the tube. Incubate 10 min at room temp (this allows transfection complexes to form).

e. Dispense the RNA/transfection agent complexes into the empty wells of a culture plate.
3. Mix cells with the RNA/transfection agent complexes
   a. Transfer cells to the culture plate containing the RNA/transfection agent complexes.
      Gently mix the cells prepared in step 1. to resuspend any that have settled, and pipet them into the culture plate containing RNA/transfection agent complexes.

   b. Gently mix the cells and RNA/transfection agent complexes.
      Rock the plate gently back and forth to evenly distribute the complexes; avoid swirling, as this can cause the transfection complexes to aggregate in the center of the well.

4. Incubate at 37°C
   Incubate the transfection mixture at 37°C until ready to assay.

5. Assay for transfection efficiency and cytotoxicity
      For initial experiments, we recommend analyzing mRNA ~48 hr after transfection or cell proliferation and protein ~72 hr after transfection. Assess both the knockdown and cell viability (see section Appendix B, “Assessing Transfection Efficiency” on page 17).
   b. Determine if further optimization is needed.
      You should expect ≥70% knockdown with ≤15% cell death from a successful transfection. If neither siPORT Amine or siPORT NeoFX gives acceptable results, use the transfection agent that gave the best results in this initial screen for subsequent optimization (section “Optimizing siRNA transfection conditions” on page 11).

---

**Optimizing siRNA transfection conditions**

The table below gives suggested ranges of transfection agent volume, RNA amount, and cell number to evaluate in optimization experiments.

<table>
<thead>
<tr>
<th>Parameter for optimization</th>
<th>Culture Plate Type</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>96-well</td>
</tr>
<tr>
<td>Transfection Agent</td>
<td>0.15, 0.3, 0.6, 1.2 µL</td>
</tr>
<tr>
<td>RNA (20 µM)†</td>
<td>0.005–0.15 µL</td>
</tr>
<tr>
<td>Cells per well</td>
<td>0.5–1 x 10⁴</td>
</tr>
<tr>
<td>Replace medium</td>
<td>8–24 hr after transfection [if cytotoxicity is observed].</td>
</tr>
</tbody>
</table>

† For ease of handling if you are not preparing master mixes, dilute the siRNA to 2 µM and use ten-fold the volume shown in the table above. Test 1–30 nM final concentration.
1. Amount of transfection agent
   The most important parameter for optimization of siRNA delivery is the amount of transfection agent used.
   a. Follow the protocol in section “Initial transfection protocol to select transfection agent” on page 10 (using 10 nM final concentration of siRNA) to test 4 different volumes of transfection agent in step 2. on page 10.
   b. Assay for target knockdown and cytotoxicity.
      • If acceptable levels of knockdown and cell viability are obtained, no further optimization is necessary.
      • If excessive cytotoxicity is observed, proceed to the next step.
      • If acceptable levels of cell viability are obtained, but knockdown is insufficient, proceed to step 3.

2. Exposure time to transfection agent (if needed)
   After determining the optimal volume of transfection agent for target knockdown, maximize cell viability by adjusting the time that cells are exposed to transfection complexes.
   a. Replace the medium at 6 hr and 24 hr after transfection by carefully aspirating the old medium from the well and adding fresh medium. It is usually not necessary to wash cells.
   b. Re-evaluate knockdown and cytotoxicity.
      • If knockdown and cell viability are acceptable, no further optimization is necessary.
      • If knockdown requires further optimization, proceed to next step.

3. Amount of siRNA
   To optimize the activity of transfected siRNAs, test 1, 3, 10, and 30 nM (final concentration) siRNA, using the transfection agent quantity and exposure time optimized in the experiments described above.
   If knockdown levels are still not acceptable, proceed to the next step.

4. Cell density
   For most adherent cells, the optimal confluency for transfection is 30–80%. The table below provides guidelines for seeding different sized culture plates to obtain 30–80% confluence after 24 hr of growth; these numbers are approximate because the exact number of cells required for seeding and transfection depends on cell type, size, and growth rate.

<table>
<thead>
<tr>
<th>Plate Type</th>
<th>Number of Cells</th>
</tr>
</thead>
<tbody>
<tr>
<td>96-well</td>
<td>0.2–2 x 10⁴</td>
</tr>
<tr>
<td>24-well</td>
<td>0.2–1 x 10⁵</td>
</tr>
<tr>
<td>12-well</td>
<td>0.5–2 x 10⁵</td>
</tr>
<tr>
<td>6-well</td>
<td>1–5 x 10⁵</td>
</tr>
</tbody>
</table>

   • Follow the transfection protocol in section “Initial transfection protocol to select transfection agent” on page 10, using the conditions optimized using the experiments described above while varying the cell plating density across the wells of the culture dish so that cells will reach between 30–80% confluency.
• Be sure to monitor cell viability during these experiments, as cell cultures can become unstable at low densities.
• Use the siRNA concentration optimized in step 3.
  The optimal cell plating density results in the greatest reduction in GAPDH expression without creating instability in the cell line.

5. Test siRNA of interest

Once an optimized protocol has been developed for a particular cell type, design and test siRNAs against your gene of interest. To identify an optimal siRNA and avoid off-target effects, we recommend testing 3 siRNAs per gene of interest. Perform transfections using the parameters established by these optimization experiments.

Troubleshooting

No detectable gene silencing

The transfection protocol requires optimization

We strongly recommend that you optimize the transfection protocol for each cell type using the control siRNAs as described in section “Optimizing siRNA transfection conditions” on page 11.

Problems with siRNA/transfection agent complex formation

Follow the instructions for transfection complex formation closely; using the appropriate incubation times is important for good transfection efficiency.

• Serum, polyanions, or other inhibitors were present during complexing.
  Although both transfection agents are compatible with serum during transfection, neither is compatible with serum during complex formation. Use Opti-MEM I reduced serum medium for siRNA/siPORT transfection agent complex formation.
• Do not overmix.
  It is important to gently mix the siRNA with the diluted transfection agent in step d. on page 10 of the reverse transfection protocol, or d. on page 22 of the traditional protocol.

Inactivated transfection agent

Store both siPORT Amine and siPORT NeoFX at 4°C. Do not allow siPORT Amine to freeze. Tightly cap tubes, because evaporation can significantly impact the activity of the transfection agents.

siRNA is degraded due to poor handling or storage

Check the integrity of the siRNA by running ~2.5 µg on a non-denaturing 15–20% acrylamide gel. Visualize the siRNA by staining with ethidium bromide, and verify that it is the expected size and intensity. The siRNA should migrate as a fairly tight band; smearing would indicate degradation.

Cells have been subcultured too many times or have undergone changes

Transfect cells within 10 passages of optimization experiments.
Troubleshooting

Transfection causes extensive cell death

Too much transfection agent was used

Titrating transfection agent over a broad dilution range, and choosing the most dilute concentration that still gives good gene knockdown.

Cells were exposed to transfection agent/siRNA complex for too long

Sensitive cells may begin to die from exposure to the transfection agent after a few hours. If transfection causes excessive cell death with your cells, remove the transfection mixture, and replenish with fresh growth medium after 8–24 hours.

Cells are stressed

- Add fresh growth medium as early as 8 hr after transfection.
- Avoid using antibiotics when plating cells for transfection, and for at least 72 hr after transfection.
- Use healthy cells that have not been grown to the point of medium depletion between subculturing events.
- Avoid subjecting cells to frequent temperature and pH shifts.

The target gene is critical for cell survival

If the target gene is critical for cell survival, reducing its expression could cause cell death. If this is the case, assay mRNA levels at earlier time points (4–24 hr).

Gene silencing experiments lack reproducibility

Transfection complexes were not adequately mixed with cells

Distribute transfection agent/RNA complex by gently rocking the plate back and forth. Do not swirl plates to mix, because this could concentrate cells and/or reagents in the center of the wells.

There were differences in the experimental procedure

The time of transfection after cell plating, incubation times, master mix volumes, and the order of component addition can all affect transfection efficiency. To obtain reproducible results in experiments involving transfection, conduct experiments exactly the same way every time.

Cell density is too low

Optimize cell density as described in section 4. on page 12. When cell density is too low, cell cultures can become unstable. This instability can vary from well to well because conditions (pH, temperature, etc.) may not be uniform across a multi-well plate, and can differentially influence unstable cultures.

Cells were passaged too many times

Repeat experiment using cells that have been subcultured fewer times.
**Related products available from Life Technologies**

<table>
<thead>
<tr>
<th>Product</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>siPORT™ NeoFX™ Transfection Agent</strong></td>
<td>siPORT™ NeoFX™ Transfection Agent was developed to streamline siRNA transfection procedures, cutting time and increasing reproducibility. This novel lipid-based formulation can be used to efficiently transfec...</td>
</tr>
<tr>
<td>Cat. nos. AM4510, AM4511</td>
<td></td>
</tr>
<tr>
<td><strong>siPORT™ Amine Transfection Agent</strong></td>
<td>siPORT™ Amine is an easy-to-use proprietary blend of polyamines that delivers siRNA into mammalian cells with minimal cytotoxicity.</td>
</tr>
<tr>
<td>Cat. nos. AM4502, AM4503</td>
<td></td>
</tr>
<tr>
<td><strong>siPORT™ siRNA Electroporation Buffer</strong></td>
<td>siPORT™ siRNA Electroporation Buffer is a low conductivity buffer optimized for delivery of siRNAs by electroporation. Designed to facilitate rapid resealing of pores induced by electroporation, siPORT™ siRNA Electroporation Buffer can...</td>
</tr>
<tr>
<td>Cat. no. AM8990</td>
<td></td>
</tr>
<tr>
<td><strong>KDalert™ GAPDH Assay Kit</strong></td>
<td>The KDalert™ GAPDH Assay Kit is a rapid, convenient, fluorescence-based method for measuring the enzymatic activity of glyceraldehyde-3-phosphate dehydrogenase (GAPDH) in cultured human, mouse, or rat cells. The KDalert™ GAPDH Assay Kit facilitates identification of optimal siRNA delivery conditions by assessment of GAPDH expression and knockdown at the protein level and integrates seamlessly with the Silencer® CellReady™ siRNA Transfection Optimization Kit (Cat. no. AM86050) and Silencer® GAPDH Control siRNAs (Cat. no. AM4605, AM4624).</td>
</tr>
<tr>
<td>Cat. no. AM1639</td>
<td></td>
</tr>
<tr>
<td><strong>Silencer® siRNAs</strong></td>
<td>Ambion® Silencer® Pre-designed siRNAs, Validated siRNAs, and siRNA Libraries are designed with the most rigorously tested siRNA design algorithm in the industry. Silencer® siRNAs are available for &gt;100,000 human, mouse, and rat targets from our searchable online database. Because of their carefully optimized design, Silencer® siRNAs are very effective, and they are guaranteed to reduce target mRNA levels by 70% or more. Furthermore, their exceptional potency means that Silencer® siRNAs effectively induce RNAi at very low concentrations, minimizing off-target effects.</td>
</tr>
<tr>
<td><strong>Silencer® siRNA Labeling Kits</strong></td>
<td>The Silencer® siRNA Labeling Kits are used for labeling siRNA synthesized with the Silencer® siRNA Construction Kit or synthesized chemically. Labeled siRNA can be used to analyze the subcellular distribution of siRNA, in vivo stability, transfection efficiency, or the capability of the siRNA to attenuate target gene expression.</td>
</tr>
<tr>
<td>Cat. no. AM1632, AM1634</td>
<td></td>
</tr>
<tr>
<td><strong>Silencer® siRNA Controls</strong></td>
<td>Silencer® siRNA Controls are chemically synthesized siRNAs for genes commonly used as controls. Validated control siRNAs are available for genes such as GAPDH, β-actin, cyclophilin, KIF11 [Eg5], GFP, and luciferase. These siRNAs are ideal for developing and optimizing siRNA experiments and have been validated for use in human cells; many are also validated in mouse and rat cells.</td>
</tr>
</tbody>
</table>

*Silencer® siRNA Transfection II Kit User Guide*
Appendix A  Supplemental Information
Related products available from Life Technologies
Assessing Transfection Efficiency

To evaluate the results of optimization experiments, evaluate both the transfection efficiency (as measured by target knockdown) and cytotoxicity (as measured by cell death) of each transfection.

Target knockdown can be assessed by looking at either mRNA levels or protein levels. Determine the siRNA-induced suppression of GAPDH mRNA or protein levels, relative to the Negative Control siRNA. The Negative Control siRNA should have no effect on the mRNA and protein levels of GAPDH; its purpose is to serve as a baseline for measuring the effects of the GAPDH siRNA. In general, successful knockdown will cause a more dramatic reduction in target mRNA levels than in target protein levels.

Cytotoxicity can be evaluated by measuring the viability of Negative Control siRNA-transfected cells under each transfection condition.

Both target knockdown (at the protein level) and cytotoxicity can be assessed in the same experiment by measuring GAPDH enzyme activity using the KDalert™ GAPDH Assay Kit (Cat. no. AM1639), described below. Other methods for separately determining target knockdown or cell viability are described as well.

Using the KDalert™ Kit to monitor cytotoxicity and GAPDH knockdown

The KDalert™ GAPDH Assay Kit streamlines determination of optimal transfection conditions by providing a rapid, convenient, fluorescence-based or colorimetric method for measuring the enzymatic activity of GAPDH in cultured cells derived from human, mouse, and rat. The general strategy for using the KDalert™ GAPDH Assay is provided below; detailed instructions are provided with the KDalert™ Kit.

GAPDH activity as a measure of cytotoxicity

GAPDH enzyme levels per cell are fairly constant in untransfected cells or in cells transfected with Negative Control siRNA. GAPDH activity in Negative Control siRNA-transfected cells can be used as an indicator of cell number, or of relative viability, under the transfection conditions being tested.

GAPDH activity as a measure of gene knockdown

The GAPDH protein knockdown for a given transfection condition is determined from the ratio of GAPDH activity in cells transfected with GAPDH siRNA to that in cells transfected with Negative Control siRNA.
Determining optimal transfection conditions with the KDalert™ Kit

Optimal transfection conditions are those which maximize specific target knockdown while minimizing transfection-associated toxicity. Target knockdown and cell viability can be measured using the KDalert™ GAPDH Assay, as described above, and then mathematically evaluated to easily determine the best transfection conditions; see the KDalert™ Kit user guide for details.

Other cell viability assays

There are many ways to assess cell viability; any established method that is appropriate for the cells in the experiment can be used. For cell viability assays to be valid, it is important to accurately count cells prior to transfection to establish a baseline viable-cell number.

a. Check visual appearance of cells for evidence of cell necrosis and/or apoptosis.

b. Measure cell viability (or total cell number) using any of the following methods:
   - Trypan blue exclusion assay
   - Alamar Blue assay
   - Acid Phosphatase or Alkaline Phosphatase assay
   - Flow cytometry
   - Fluorescence microscopy

Other assays for gene knockdown

Quantitating mRNA levels by Northern analysis or RT-PCR

Determine the siRNA-induced suppression of GAPDH mRNA or protein levels, relative to the Negative Control siRNA. We recommend analyzing 18S rRNA levels as a means to normalize the GAPDH mRNA data. The GAPDH siRNA typically reduces GAPDH mRNA levels 70–90%, 48 hr after transfection. Either of the following methods can be used to determine mRNA levels:

a. Northern blot: Follow standard Northern procedures. Alternatively, Life Technologies offers kits and reagents for probe-labeling and Northern blotting (see our catalog for details). We recommend using the RNAqueous® Kit (Cat. no. AM1912) or RiboPure™ Kit (Cat. no. AM1924) for RNA isolation.

b. Real-time PCR: We recommend the following products to facilitate real-time PCR analysis of RNAi:
   - The RNAqueous® Kit (Cat. no. AM1912) or RiboPure™ Kit (Cat. no. AM1924) for RNA isolation followed by the RETROscript® (Cat. no. AM1710) procedure to produce cDNA.
   - The Cells-to-Signal™ Kit (Cat. no. AM1724, AM1726) for synthesis of cDNA directly from cell lysates without RNA isolation—the cDNA or the lysate itself can then be used in real-time PCR.
• Applied Biosystems’ TaqMan® Gene Expression Assays, an extensive collection of gene-specific primer-probe sets for real-time PCR (www.allgenes.com).

Quantitate protein levels by Western blot, immunohistochemistry, or immunofluorescence

The knockdown can also be determined from protein levels, by Western blot or immunostaining. In a successful transfection with the GAPDH siRNA, protein levels are typically reduced by 70–90%, 72 hr after transfection. Life Technologies offers select antibodies for siRNA research (anti-GAPDH, mouse monoclonal, Cat. no. AM4300).
Appendix B  Assessing Transfection Efficiency

Other assays for gene knockdown
**Traditional “Pre-plating” Transfection Protocol**

**Traditional transfection protocol**

The following protocol is a traditional “pre-plating” method. It requires more time than reverse transfection, but may be more effective with some cell types.

<table>
<thead>
<tr>
<th>Protocol step</th>
<th>Reagent</th>
<th>96-well</th>
<th>24-well</th>
<th>12-well</th>
<th>6-well</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Cell plating</td>
<td>Plate cells (per well)</td>
<td>~10^4</td>
<td>2~10 x 10^4</td>
<td>0.5~2 x 10^5</td>
<td>1~5 x 10^5</td>
</tr>
<tr>
<td>2. Prepare siRNA/transfection agent complexes</td>
<td>Dilute Transfection agent in Opti-MEM I to:</td>
<td>0.15~1.2 µL</td>
<td>0.5~4 µL</td>
<td>1~6 µL</td>
<td>3~9 µL</td>
</tr>
<tr>
<td></td>
<td>Dilute small RNA (20 µM)† in OPTI-MEM I to:</td>
<td>0.005~0.15 µL</td>
<td>0.025~0.75 µL</td>
<td>0.05~1.5 µL</td>
<td>0.125~3.75 µL</td>
</tr>
<tr>
<td>3. Transfect cells</td>
<td>Adjust medium in wells to:</td>
<td>80 µL</td>
<td>450 µL</td>
<td>900 µL</td>
<td>2300 µL</td>
</tr>
<tr>
<td></td>
<td>Final transfection volume</td>
<td>~100 µL</td>
<td>~500 µL</td>
<td>~1000 µL</td>
<td>~2500 µL</td>
</tr>
<tr>
<td></td>
<td>Add fresh normal growth medium after 8~48 hr</td>
<td>100 µL</td>
<td>0.5~1 mL</td>
<td>1~2 mL</td>
<td>1~3 mL</td>
</tr>
</tbody>
</table>

† This gives a final concentration of 1~30 nM. If not preparing a master mix, we recommend diluting the stock siRNA to 1~2 µM using nuclease-free water or Opti-MEM I for easier handling.

**IMPORTANT!** The volumes and amounts in the following protocol are for transfection in a 24-well plate.

1. Cell plating
   a. Approximately 24 hr before transfection, plate cells in normal growth medium (e.g., DMEM, 10% FBS) so that they will be 30~80% confluent after 24 hr. (see table above for an estimate of how many cells to plate).
   b. Incubate the cells overnight under normal cell culture conditions.

2. Prepare siRNA/transfection agent complexes
   a. Briefly vortex the transfection agent before use.
b. Dilute the transfection agent into OPTI-MEM I reduced serum medium.
   i. In a sterile, round-bottom (or V-bottom) 96 well tissue culture dish or in
      sterile polystyrene tube, dilute 1–3 µL of transfection agent dropwise into
      OPTI-MEM I reduced serum medium for a final volume of 25 µL.
   ii. Vortex well, and then incubate at room temp 10–15 min.

c. Dilute 0.025–0.75 µL of 20 µM siRNA (for a final concentration of 1–30 nM)
   into OPTI-MEM I for a final volume of 25 µL.

d. Add diluted siRNA to diluted transfection agent; mix by gently flicking the
   tube or pipetting.

e. Incubate at room temp for 10–15 min.

3. Transfect cells
   a. Adjust the volume of normal growth medium (e.g., DMEM, 10% FBS) in a
      well containing cells to 450 µL.
   b. Add the transfection agent/siRNA complex from step 2e. dropwise to the
      cells (the final transfection volume will be 500 µL).
   c. Without swirling, gently rock the dish back and forth to evenly distribute the
      complexes.
   d. Incubate cells under normal cell culture conditions for 48 hr.
   e. 0.5–1 mL fresh normal growth medium may be added to each well after
      8–48 hr to maximize cell growth and prevent potential cytotoxicity.

4. Assay for target gene activity 8–72 hr after transfection
   For initial experiments, we recommend analyzing mRNA ~48 hr after transfection
   or protein ~72 hr after transfection. Assess both knockdown and cell viability (see
   Plasmid DNA can be cotransfected with small RNAs using the Silencer siRNA
   Transfection II Kit. Typically, both circular and linearized plasmids less than 10 kb
   can be effectively transfected. Plasmids larger than 10 kb must be linearized for
   efficient transfection.

Protocol modification for cotransfection

To cotransfect plasmid DNA and siRNA using the Silencer siRNA Transfection II Kit,
modify the standard protocol as follows:

Add DNA with the RNA in step 2.c. on page 10 of the protocol. Continue the protocol
as described.

Optimization

It is important to optimize the amount of DNA used in transfection. Transfection
efficiency depends more on the ratio of DNA to transfection agent (µg/µL) than on the
overall amount of DNA.
Chemical safety

**WARNING! GENERAL CHEMICAL HANDLING.** To minimize hazards, ensure laboratory personnel read and practice the general safety guidelines for chemical usage, storage, and waste provided below, and consult the relevant SDS for specific precautions and instructions:
Read and understand the Safety Data Sheets (SDSs) provided by the chemical manufacturer before you store, handle, or work with any chemicals or hazardous materials. To obtain SDSs, see the “Documentation and Support” section in this document:

- Minimize contact with chemicals. Wear appropriate personal protective equipment when handling chemicals (for example, safety glasses, gloves, or protective clothing).
- Minimize the inhalation of chemicals. Do not leave chemical containers open. Use only with adequate ventilation (for example, fume hood).
- Check regularly for chemical leaks or spills. If a leak or spill occurs, follow the manufacturer’s cleanup procedures as recommended in the SDS.
- Handle chemical wastes in a fume hood.
- Ensure use of primary and secondary waste containers. (A primary waste container holds the immediate waste. A secondary container contains spills or leaks from the primary container. Both containers must be compatible with the waste material and meet federal, state, and local requirements for container storage.)
- After emptying a waste container, seal it with the cap provided.
- Characterize (by analysis if necessary) the waste generated by the particular applications, reagents, and substrates used in your laboratory.
- Ensure that the waste is stored, transferred, transported, and disposed of according to all local, state/provincial, and/or national regulations.
- **IMPORTANT!** Radioactive or biohazardous materials may require special handling, and disposal limitations may apply.

Biological hazard safety

**WARNING! Potential Biohazard.** Depending on the samples used on this instrument, the surface may be considered a biohazard. Use appropriate decontamination methods when working with biohazards.
WARNING! BIOHAZARD. Biological samples such as tissues, body fluids, infectious agents, and blood of humans and other animals have the potential to transmit infectious diseases. Follow all applicable local, state/provincial, and/or national regulations. Wear appropriate protective equipment, which includes but is not limited to: protective eyewear, face shield, clothing/lab coat, and gloves. All work should be conducted in properly equipped facilities using the appropriate safety equipment (for example, physical containment devices). Individuals should be trained according to applicable regulatory and company/institution requirements before working with potentially infectious materials. Read and follow the applicable guidelines and/or regulatory requirements in the following:

In the U.S.:
- U.S. Department of Health and Human Services guidelines published in Biosafety in Microbiological and Biomedical Laboratories found at: www.cdc.gov/biosafety
- Occupational Safety and Health Standards, Bloodborne Pathogens (29 CFR§1910.1030), found at: www.access.gpo.gov/nara/cfr/waisidx_01/29cfr1910a_01.html
- Your company’s/institution’s Biosafety Program protocols for working with/handling potentially infectious materials.
- Additional information about biohazard guidelines is available at: www.cdc.gov

In the EU:
Documentation and Support

Obtaining SDSs

Safety Data Sheets (SDSs) are available from www.lifetechnologies.com/support

Note: For the SDSs of chemicals not distributed by Life Technologies, contact the chemical manufacturer.

Obtaining support

For the latest services and support information for all locations, go to:

www.lifetechnologies.com/support

At the website, you can:

- Access worldwide telephone and fax numbers to contact Technical Support and Sales facilities
- Search through frequently asked questions (FAQs)
- Submit a question directly to Technical Support (techsupport@lifetech.com)
- Search for user documents, SDSs, vector maps and sequences, application notes, formulations, handbooks, certificates of analysis, citations, and other product support documents
- Obtain information about customer training
- Download software updates and patches

Limited product warranty

Life Technologies Corporation and/or its affiliate(s) warrant their products as set forth in the Life Technologies’ General Terms and Conditions of Sale found on Life Technologies’ website at www.lifetechnologies.com/termsandconditions. If you have any questions, please contact Life Technologies at www.lifetechnologies.com/support
